| Followers | 200 |
| Posts | 25584 |
| Boards Moderated | 0 |
| Alias Born | 04/03/2010 |
Thursday, December 28, 2017 9:59:13 AM
Thanks spartex. Yes, I understand the many voices becoming anxious to hear news. I see this in many of my stocks when there is any extended period of silence, which happens quite often in biotechs for a variety of reasons, and in my experience, it frequently is not necessarily indicative of one thing or another, but often is just a result of necessary circumstances, though it's also possible that they are stalling. My hunch is that they are awaiting publication of results and are embargoed. But I certainly could be wrong.
They could also be answering key questions that peer review might raise, just as key questions are raised here. With so many trial centers and so much data, it might take longer than people presume. I have no idea, but given the data through last September, I'm optimistic. That people on twitter and the usual talking heads there, AF, and his fanboys are saying that silence is terrible, is more of the same from them. I don't take much of it seriously. In fact, I'd suggest rather that their posts and twitter remarks are intended to condition the market for their own critique no matter what is in the report. We all have some idea that some patients (mesenchymal) could very likely do better than others, and we know that AF and crew will attempt to suggest a positive report is a cover-up. That's what they do. They are conditioning the market for their critique now, even going so far as to cc' the SEC in their tweets, so that it appears they are "whistle blowers". The SEC has no part in the activity and can't comment, and by cc'ing them, it looks like they are acting above board (or pretending to intend to do so). We know they will do this because, they have told us that they will do it, and we can expect that this has been their disposition since the beginning, no matter what the news was and no matter how positive it was. For me, it's noise though certainly others may think it is very, very serious and of great concern. Everyone has their level of tolerance for being in the dark, and also will have their worries once the [expletive] let their bs fly. BS they've already planned out thoroughly without actually knowing the results.
They could also be answering key questions that peer review might raise, just as key questions are raised here. With so many trial centers and so much data, it might take longer than people presume. I have no idea, but given the data through last September, I'm optimistic. That people on twitter and the usual talking heads there, AF, and his fanboys are saying that silence is terrible, is more of the same from them. I don't take much of it seriously. In fact, I'd suggest rather that their posts and twitter remarks are intended to condition the market for their own critique no matter what is in the report. We all have some idea that some patients (mesenchymal) could very likely do better than others, and we know that AF and crew will attempt to suggest a positive report is a cover-up. That's what they do. They are conditioning the market for their critique now, even going so far as to cc' the SEC in their tweets, so that it appears they are "whistle blowers". The SEC has no part in the activity and can't comment, and by cc'ing them, it looks like they are acting above board (or pretending to intend to do so). We know they will do this because, they have told us that they will do it, and we can expect that this has been their disposition since the beginning, no matter what the news was and no matter how positive it was. For me, it's noise though certainly others may think it is very, very serious and of great concern. Everyone has their level of tolerance for being in the dark, and also will have their worries once the [expletive] let their bs fly. BS they've already planned out thoroughly without actually knowing the results.
Recent NWBO News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/26/2025 05:15:34 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
